Cargando…

Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response

Background: LC has been associated with hyporesponsiveness to several vaccines. Nonetheless, no data on complete serological and B- and T-cell immune response are currently available. Aims: To assess, in comparison with healthy controls of the same age and gender, both humoral and cellular immunores...

Descripción completa

Detalles Bibliográficos
Autores principales: Giambra, Vincenzo, Piazzolla, Annarita Valeria, Cocomazzi, Giovanna, Squillante, Maria Maddalena, De Santis, Elisabetta, Totti, Beatrice, Cavorsi, Chiara, Giuliani, Francesco, Serra, Nicola, Mangia, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415026/
https://www.ncbi.nlm.nih.gov/pubmed/36016169
http://dx.doi.org/10.3390/vaccines10081281
_version_ 1784776131135668224
author Giambra, Vincenzo
Piazzolla, Annarita Valeria
Cocomazzi, Giovanna
Squillante, Maria Maddalena
De Santis, Elisabetta
Totti, Beatrice
Cavorsi, Chiara
Giuliani, Francesco
Serra, Nicola
Mangia, Alessandra
author_facet Giambra, Vincenzo
Piazzolla, Annarita Valeria
Cocomazzi, Giovanna
Squillante, Maria Maddalena
De Santis, Elisabetta
Totti, Beatrice
Cavorsi, Chiara
Giuliani, Francesco
Serra, Nicola
Mangia, Alessandra
author_sort Giambra, Vincenzo
collection PubMed
description Background: LC has been associated with hyporesponsiveness to several vaccines. Nonetheless, no data on complete serological and B- and T-cell immune response are currently available. Aims: To assess, in comparison with healthy controls of the same age and gender, both humoral and cellular immunoresponses of patients with LC after two or three doses of the mRNA Pfizer-BioNTech vaccine against SARS-CoV-2 and to investigate clinical features associated with non-response. Material and methods: 179 patients with LC of CTP class A in 93.3% and viral etiology in 70.1% of cases were longitudinally evaluated starting from the day before the first dose to 4 weeks after the booster dose. Their antibody responses were compared to those of healthcare workers without co-morbidities. In a subgroup of 40 patients, B- and T-cell responses were also compared to controls. Results: At d31, d90 and d180 after BNT162b2 vaccine, no detectable SARS-CoV-2 IgG response was observed in 5.9%, 3.9% and 7.2% of LC patients as compared to 0 controls (p < 0.03). A delay in B-cell and lack of prompt T-cell response compared to healthcare workers was also registered. A significant correlation between antibody titers and cellular response was observed. A MELD score > 8 was the only independent predictor of poor d31 response (p = 0.028). Conclusions: Our results suggest that cirrhotic patients have a slower and in <10% suboptimal immune response to SARS-CoV-2 vaccination. Rates of breakthrough infections were comparable between cirrhotics and controls. The booster dose was critical in inducing both humoral and cellular responses comparable to controls.
format Online
Article
Text
id pubmed-9415026
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94150262022-08-27 Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response Giambra, Vincenzo Piazzolla, Annarita Valeria Cocomazzi, Giovanna Squillante, Maria Maddalena De Santis, Elisabetta Totti, Beatrice Cavorsi, Chiara Giuliani, Francesco Serra, Nicola Mangia, Alessandra Vaccines (Basel) Article Background: LC has been associated with hyporesponsiveness to several vaccines. Nonetheless, no data on complete serological and B- and T-cell immune response are currently available. Aims: To assess, in comparison with healthy controls of the same age and gender, both humoral and cellular immunoresponses of patients with LC after two or three doses of the mRNA Pfizer-BioNTech vaccine against SARS-CoV-2 and to investigate clinical features associated with non-response. Material and methods: 179 patients with LC of CTP class A in 93.3% and viral etiology in 70.1% of cases were longitudinally evaluated starting from the day before the first dose to 4 weeks after the booster dose. Their antibody responses were compared to those of healthcare workers without co-morbidities. In a subgroup of 40 patients, B- and T-cell responses were also compared to controls. Results: At d31, d90 and d180 after BNT162b2 vaccine, no detectable SARS-CoV-2 IgG response was observed in 5.9%, 3.9% and 7.2% of LC patients as compared to 0 controls (p < 0.03). A delay in B-cell and lack of prompt T-cell response compared to healthcare workers was also registered. A significant correlation between antibody titers and cellular response was observed. A MELD score > 8 was the only independent predictor of poor d31 response (p = 0.028). Conclusions: Our results suggest that cirrhotic patients have a slower and in <10% suboptimal immune response to SARS-CoV-2 vaccination. Rates of breakthrough infections were comparable between cirrhotics and controls. The booster dose was critical in inducing both humoral and cellular responses comparable to controls. MDPI 2022-08-08 /pmc/articles/PMC9415026/ /pubmed/36016169 http://dx.doi.org/10.3390/vaccines10081281 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Giambra, Vincenzo
Piazzolla, Annarita Valeria
Cocomazzi, Giovanna
Squillante, Maria Maddalena
De Santis, Elisabetta
Totti, Beatrice
Cavorsi, Chiara
Giuliani, Francesco
Serra, Nicola
Mangia, Alessandra
Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response
title Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response
title_full Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response
title_fullStr Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response
title_full_unstemmed Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response
title_short Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response
title_sort effectiveness of booster dose of anti sars-cov-2 bnt162b2 in cirrhosis: longitudinal evaluation of humoral and cellular response
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415026/
https://www.ncbi.nlm.nih.gov/pubmed/36016169
http://dx.doi.org/10.3390/vaccines10081281
work_keys_str_mv AT giambravincenzo effectivenessofboosterdoseofantisarscov2bnt162b2incirrhosislongitudinalevaluationofhumoralandcellularresponse
AT piazzollaannaritavaleria effectivenessofboosterdoseofantisarscov2bnt162b2incirrhosislongitudinalevaluationofhumoralandcellularresponse
AT cocomazzigiovanna effectivenessofboosterdoseofantisarscov2bnt162b2incirrhosislongitudinalevaluationofhumoralandcellularresponse
AT squillantemariamaddalena effectivenessofboosterdoseofantisarscov2bnt162b2incirrhosislongitudinalevaluationofhumoralandcellularresponse
AT desantiselisabetta effectivenessofboosterdoseofantisarscov2bnt162b2incirrhosislongitudinalevaluationofhumoralandcellularresponse
AT tottibeatrice effectivenessofboosterdoseofantisarscov2bnt162b2incirrhosislongitudinalevaluationofhumoralandcellularresponse
AT cavorsichiara effectivenessofboosterdoseofantisarscov2bnt162b2incirrhosislongitudinalevaluationofhumoralandcellularresponse
AT giulianifrancesco effectivenessofboosterdoseofantisarscov2bnt162b2incirrhosislongitudinalevaluationofhumoralandcellularresponse
AT serranicola effectivenessofboosterdoseofantisarscov2bnt162b2incirrhosislongitudinalevaluationofhumoralandcellularresponse
AT mangiaalessandra effectivenessofboosterdoseofantisarscov2bnt162b2incirrhosislongitudinalevaluationofhumoralandcellularresponse